Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | — |
The patient took the second and the third dose of Vivotif two days in a row; Case reference number US-BN-2024-000084 is a spontaneous case report initially received from nurse via Med Communications (reference number: USBAV24-0120) on 19-Jan-2024 and concerns a female patient. The patient's medical history and concomitant medication details were not provided. On 15-Jan-2024, the patient took the first dose of Vivotif (batch number: unknown), at an unknown dose or route of administration, for unknown indication. On 17-Jan-2024, two days after first dose of Vivotif, the patient took the second dose of Vivotif (batch number: unknown), at an unknown dose or route of administration. On 18-Jan-2024, three days after first dose of Vivotif, as reported two days in a row with the second dose, the patient took the third dose of Vivotif (batch number: unknown), at an unknown dose or route of administration, for unknown indication (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine. No further information was provided.; Reporter's Comments: A female patient took the second and third dose of Vivotif, two days in a row for an unknown indication, which is considered as inappropriate schedule of vaccine administered. No associated adverse events were reported. Inappropriate schedule of vaccine administered is listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to Vivotif, but to a human factor. The case is non-serious.; Sender's Comments: A female patient took the second and third dose of Vivotif, two days in a row for an unknown indication, which is considered as inappropriate schedule of vaccine administered. No associated adverse events were reported. Inappropriate schedule of vaccine administered is listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to Vivotif, but to a human factor. The case is non-serious.
Comments: None